Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Oncology
0
Pipeline Programs
1
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
OdronextamabN/AMonoclonal Antibody5 trials
Active Trials
NCT05619367Available
NCT06149286Recruiting470Est. Jan 2029
NCT06091865Active Not Recruiting904Est. Sep 2029
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
RegeneronOdronextamab
RegeneronOdronextamab
RegeneronOdronextamab
RegeneronOdronextamab

Clinical Trials (5)

Total enrollment: 1,665 patients across 5 trials

NCT06149286RegeneronOdronextamab

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Start: Dec 2023Est. completion: Jan 2029470 patients
Phase 3Recruiting
NCT06091865RegeneronOdronextamab

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Start: Dec 2023Est. completion: Sep 2029904 patients
Phase 3Active Not Recruiting
NCT05685173RegeneronOdronextamab

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Start: Apr 2023Est. completion: May 202991 patients
Phase 1Recruiting
NCT02290951RegeneronOdronextamab

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Start: Jan 2015Est. completion: Aug 2025200 patients
Phase 1Completed
NCT05619367RegeneronOdronextamab

A Compassionate Use (CU) Program of Odronextamab

N/AAvailable

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,665 patients
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)